Cellseed Inc. · TSE:7776
Cellseed — H1 2023 Earnings Presentation
32 slides from Cellseed's earnings presentation, Sep 27, 2023
Slide 1: Fiscal 2023 First-Half Earnings Results Presentation
)CcellSeed Regenerate the Future CellSeed Inc. Fiscal 2023 First-Half Earnings Results Presentation Tokyo Stock Exchange Growth Code:7776
Slide 2: Contents
Contents DcelliSeed TTD TNT II © Company Profile @ Financial Summary Second Quarter of Fiscal Year Ending December 31, 2023 @ Progress of each business © 2023 CellSeed Inc. 1
Slide 3: Head office, CPC development and manufacturing facility
Head office -CPC-development and manufacturing facility PCellSeed TT TTD ANTI OI Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed Tokyo Stock Exchange Growth (7776) Head Office Telecom Center » 45K (East Win , 15F (East Wing) Telecom Center
Slide 4: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information peousced AA II IIT I Tn Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Regenerative Medical Regenerative Medicine Products Business Supporting Business @ Commercialization of Cell
Slide 5: Our Business Model
Our Business Model PceliSeed Medical Seeds Products Treatment ay <<>> —=> + )cellSeed o Ss Regenerate the Future | ———— ee = Collaborative Fee i a Research Business Alliance Partner Companies © 2023 CellSeed Inc. 4
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering celiseea Regenerate the Future Cartilage Pancreas © 2023 CellSeed Inc. 5
Slide 7: Contents
Contents DcellSeed © Financial Summary Second Quarter of Fiscal Year Ending December 31, 2023 © 2023 CellSeed Inc. 6
Slide 8: Half-year financial summary FY 12/2023
Half-year financial summary FY 12/2023 DcellSeed Regenerate the Future First Half of the FY2023 First Half of the FY2022 (January 2023 - June 2023) (January 2022 - June 2022) Change from nge from . esl Previous Period | Previous Period . unas (Millions of yen) Millions of yen (Millions of yen) Opera
Slide 9: Differences between the estimates and results in the second quarter
Differences between the estimates and results in the second Pceliseed quarter of the term ending December 2023 Ragenerate the Future [unit: million yen, rounded down to the nearest million] Operating Ordinary profit profit Previously announced forecasts (announced on Feb. 14, 2023) 95 -450 -450 -455
Slide 10: Issuance of share acquisition rights to a third party
The 24 issuance of share acquisition rights (with a provision for revising )cellSeed exercise price) for allocation of shares to a third party Regenerate the Future ALN TTT TTI I Allocation date June 5, 2023 Number of share acquisition rights to 69,000 be issued Allocatee Barclays Bank Assumed procu
Slide 11: Contents
Contents DcelliSeed @ Company Profile @ Financial Summary Second Quarter of Fiscal Year Ending December 31, 2023 © Progress of each business © 2023 CellSeed Inc. 10
Slide 12: Cell cultureware in the regenerative medicine supporting business
Cell cultureware in the regenerative medicine supporting business? Cellseed Regenerate the Future : Professor Okano of Tokyo Women’s Medical Temperature-responsive cell cultureware 1989 University invented temperature-responsive cell cultureware. invented by Professor Okano of Tokyo 2004 Released Re
Slide 13: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup )cellSeed Regenerate the Future NI I (— >) ( > UpCell® RepCell® This cultureware In addition to the same maintains the . <=, characteristics as those physiological activity of ~ i? of UpCell®, this \ A A S , cells and retains a high ieee aw cult
Slide 14: Upcoming plans for Cultureware business
Upcoming plans for Cultureware buisiness Sel!/Seed © Overseas sales of UpCell® flasks will start soon & © UpCell user training services will start soon @ Training for UpCell users will be held at the Aomi Cell Culture Innovation Center. @ We will actually give a lecture on tips for making cell sheet
Slide 15: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware PCellSeed eee Recently, the production of bio-pharmaceutical products using mass-cultured cells, the immunotherapy using cells, and initiatives for solving food and environmental issues have been active. In the generally used cell collection technology
Slide 16: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business _—_Sel/seed Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products @ Development of cell sheet manufacturing methods @ Contract manufacturing of cell sheet products @ Quality testing of cell sheets, etc. Facility Management
Slide 17: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service PCeliSeed TT SLIT TOS IEEE OTL A For the regenerative medicine service, we obtained the permission to manufacture specific processed cells (facility No. FA3160008) in March 2017 and the permission to manufacture products for regenerative med
Slide 18: New deal of our contract services
New deal of our contract services PCeliSeed ® Contract manufacturing of autologous chondrocyte sheets for self-pay medical treatment at Ikegami General Hospital Target patients : Patients with knee cartilage due to trauma or knee OA @ Patients who are not eligible for advanced Medical Care provided
Slide 19: Pipeline Progress
Pipeline Progress NI I Regenerative medicine )CcellSeed Regenerate the Future = Pipeline First phase Third phase phase Fundamental Clinical Clinical trials Application research research Second /approval Epithelial Cell ceoehageal Currently conducting clinical trials under the Pharmaceutical and Medi
Slide 20: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration »celiseed (CLS2702C/D) Regenerate the Future ATI I TIO EI ©® A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) © Cell sheet is on a tem
Slide 21: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet »celiseed Regenerate the Future Tokyo Women’s . _ ___,.,__ Medical University @ Clinical Research at Universities 2008 — 2014 <Japan> Tokyo Women’s Medical Univ. 10case Basic Tokyo Women’s Medical Univ. and Nagasaki Univ. fgets Developme
Slide 22: Knee Osteoarthritis (OA)
Knee Osteoarthritis (OA) dled @ Prevalence increases with age S ~~ @ 1.5 to 2 times more women “s than men 30 million 10 million patients @ Number of patients is expected potential patients with symptoms to increase due to aging of the Gapan) (Japan) population No fundamental medical therapy for OA
Slide 23: Process of producing allogeneic cartilage cell sheets
Process of producing allogeneic cartilage cell sheets )cellseed (CLS2901C) Mecha Cell Bank An extra finger excised from a F patient with ~ Semination fone Ampiiied polydactyly a P1 Cell Stock i (Master Cell Bank) PX Working Cell Bank Implantation Pre-culture Sheet forming r | =e mon Senn - —s S PX W
Slide 24: Safety testing of cell banks and cell sheets
Safety testing of cell banks and cell sheets pdr Cell Bank Cell number, Cell viability, Sterility test, Endotoxins test, Virus test, Mycoplasma test, and so on An extra finger excised from a 4 Isolated ae Frozen Amplified Pe dactvly cartilage Semination storage ulture P1 Cell Stock a = (Master Cell
Slide 25: Safety testing of cell banks and cell sheets
Safety testing of cell banks and cell sheets pceliseed eee Pi 5... (Master Cell Bank) © 2023 CellSeed Inc. 24
Slide 26: Efficacy of allogeneic chondrocyte sheets
Efficacy of allogeneic chondrocyte sheets PCeliSeed Regenerate the Future TT © 2023 CellSeed Inc. 25
Slide 27: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets peclisced an. Clinical Research at Tokai University 2019 Completed in December 2019 transplants of 10 cases Adopted as the ancillary project of AMED Adopted as “a project for developing fundamental evaluation technologies for industrializing regenerative medicine (suppo
Slide 28: Steps for conducting clinical trial
PcellSeed Steps for conducting clinical trial cerita NI I Non-Clinical tests (Safety - Efficacy: Quality) PMDA Reviews uejd |eL} u ie] =) 2. =) ie) ° fe} Q 3. fe} o © 2023 CellSeed Inc. ueld jel [Ed!UI|D JO aUIANO Ueld JelLL [EOI Jo uonezieuly UONeIIJHOU [el4} jedlul|D JO UOISSILUqNS MalAasd Aep-og
Slide 29: Cell Sheet Engineering Innovation Forum
34 Cell Sheet Engineering Innovation Forum PCeliSeed AA II IIT I Tn @ Date : Friday, Nov. 24, 2023 @ Venue : Miraikan Hall on the 7th floor of the National Museum of . Emerging Science and Innovation, etc. @ Seating capacity : 200 people (pre-registration, first come, first served) @ Attendance : Fr
Slide 30: Scenes from past Cell Sheet Engineering Innovation Forums
Scenes from past Cell Sheet Engineering Innovation Forums 2¢el/Seed © 2023 CellSeed Inc. 29
Slide 31: Announcements Regarding Certain Media
Announcements Regarding Certain Media YcellSeed (@eh falas ges OD Metate cACAP) Inc in Taiwan Regenerate the Future @ Recent reports in some Taiwanese media regarding MetaTech ™@ Our “cell sheet engineering” information was leaked from MetaTech m MetaTech is conducting research and development of al
Slide 32: DcellSeed
DcellSeed Regenerate the Future This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © CellSeed Inc. All Rights Reserved.